Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide ...

The research team used a special type of CT scan along with a dye called metomidate. This dye attaches specifically to the cells that produce aldosterone. Because the dye contains a very small amount ...

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the ...

Research and Development (R&D) expenses: R&D expenses were $13.7 million for the three months ended December 31, 2025, compared to $6.0 million for the comparable period in 2024, and were $46.7 ...